Results 1 to 10 of about 180,829 (383)

HuMab-7D8, a monoclonal antibody directed against the membrane-proximal small loop epitope of CD20 can effectively eliminate CD20low expressing tumor cells that resist rituximab-mediated lysis

open access: yesHaematologica, 2010
Background Incorporation of the chimeric CD20 monoclonal antibody rituximab in the treatment schedule of patients with non-Hodgkin’s lymphoma has significantly improved outcome. Despite this success, about half of the patients do not respond to treatment
Tom van Meerten   +10 more
doaj   +1 more source

Systemic mastocytosis with associated myeloproliferative disease and precursor B lymphoblastic leukaemia with t(13;13)(q12;q22) involving FLT3. [PDF]

open access: yes, 2008
Systemic mastocytoses represent neoplastic proliferations of mast cells. In about 20% of cases systemic mastocytoses are accompanied by clonal haematopoietic non-mast cell-lineage disorders, most commonly myeloid neoplasms.
Dirnhofer, S.   +7 more
core   +1 more source

Expression of Epstein–Barr Virus–Encoded Small RNA (by the EBER-1 Gene) in Liver Specimens from Transplant Recipients with Post-Transplantation Lymphoproliferative Disease [PDF]

open access: yes, 1992
Epstein-Barr virus (EBV)—associated post-transplantation lymphoproliferative disease (PTLD) develops in 1 to 10 percent of transplant recipients, in whom it can be treated by a reduction in the level of immunosuppression.
Anthony J. Demetris   +26 more
core   +1 more source

Prognostic Significance of Cancer Stem Cell Markers and Tumor Microenvironment Components for Assessing the Efficacy of Chemoradiotherapy in Patients with Locally Advanced rectal cancer

open access: yesИнновационная медицина Кубани
Background: Despite the incorporation of neoadjuvant chemoradiotherapy into the standard treatment of locally advanced rectal cancer, significant variability in therapeutic response persists.
A. Yu. Georgieva   +2 more
doaj   +1 more source

Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist during Treatment with Rituximab

open access: yesClinical Medicine Insights: Oncology, 2008
Potential progenitor B cell compartments in multiple myeloma (MM) are clinically important. MM B cells and some circulating MM plasma cells express CD20, predicting their clearance by treatment with anti-CD20.
Linda M. Pilarski   +6 more
doaj   +1 more source

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis [PDF]

open access: yes, 2019
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ...
Altieri, Marta   +11 more
core   +1 more source

Immune cells and tryptophan metabolism in the joint capsule tissue in rheumatoid arthritis

open access: yesActa Biomedica Scientifica
To the present day, many links in the pathogenesis of rheumatoid arthritis remain unclear, which leads to unsatisfactory results in its therapy.The aim.
E. A. Stepanov
doaj   +1 more source

Population Pharmacokinetics and CD20 Binding Dynamics for Mosunetuzumab in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL) [PDF]

open access: bronze, 2023
Brendan C. Bender   +13 more
openalex   +1 more source

Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies [PDF]

open access: yes, 2000
Acquired hemophilia, caused by autoantibodies against coagulation factor VIII, is usually treated with steroids, cyclophosphamide, intravenous gammaglobulins and sporadically other drugs.
Baele, Gaston   +2 more
core  

Metric geodesics of isometries in a Hilbert space and the extension problem [PDF]

open access: yes, 2007
We consider the problem of finding short smooth curves of isometries in a Hilbert space H. The length of a smooth curve γ(t), t ∈ [0, 1], is measured by means of ∫^1-0 γ^. (t)ǀǀ dt, where ǀǀ ǀǀ denotes the usual norm of operators.
Andruchow, Esteban   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy